Table 2. Summary of studies comparing coronary revascularisation approaches in ESRD (dialysis-dependent).

	Study design	Study size	ESRD	Comparison/intervention	DES stent use	Primary outcome	Secondary outcomes	All-cause mortality	Stent thrombosis	Repeat revascularisation	Non-fatal MI	Additional comments	Follow-up period	Inclusion period
Li et al3	Meta-analysis	62,250	62,250 (100%)	DES vs. BMS	NR	All-cause mortality MI MACE TVR/TLR	NA	Favours DES	NR	Favours DES	Non-significant difference	NA	NR	2006-2016
Ishii et al29	Retrospective	505	505	DES vs. BMS	SES, PES	TLR	Composite of cardiovascular death, non-fatal MI, ST, TLR	Non-significant difference	Non-significant difference	Favours DES (beyond 1 year)	Non-significant difference	NA	42 months	1999-2009
Saka­kibara et al32	Single-centre prospective	100	100	DES-I vs. DES-II	SES (50%), EES (50%)	Restenosis at 8-month follow-up	MACE (all-cause death, non-fatal MI, TLR)	Non-significant difference	Non-significant difference	Non-significant difference	Non-significant difference	EES reduced restenosis rates compared to SES	8 months	2010
Nevis et al38	Systematic review	32,388	32,388 (100%)	CABG vs. PCI	NR	Short-term (30 days) or long-term (>1 year) mortality	NA	Short-term: favours PCI Long-term: favours CABG	NA	Favours CABG	Favours CABG	NA	PCI: 28 months CABG: 31 months	1991-2007
BMS: bare metal stent; CABG: coronary artery bypass grafting; CKD: chronic kidney disease; DES: drug-eluting stent; DES-I: first-generation DES; DES-II: second-generation DES; EES: everolimus-eluting stent; ESRD: end-stage renal disease; MACE: major adverse cardiac events; MI: myocardial infarction; NA: not applicable; NR: not recorded; PCI: percutaneous coronary intervention; SES: sirolimus-eluting stent; ST: stent thrombosis; TLR: target lesion revascularisation; TVF: target vessel failure; TVR: target vessel revascularisation